Rubin DT - Search Results

1

Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.

Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, Gatopoulou A, Karatzas P, Kopylov U, Michalopoulos G, Michopoulos S, Navaneethan U, Rubin DT, Siffledeen J, Singh A, Soufleris K, Stein D, Demuth D, Mantzaris GJ. Bressler B, et al. Among authors: rubin dt. J Crohns Colitis. 2021 Oct 7;15(10):1694-1706. doi: 10.1093/ecco-jcc/jjab058. J Crohns Colitis. 2021. PMID: 33786600 Free PMC article.

2

Role of antibiotics in the management of inflammatory bowel disease: a review.

Rubin DT, Kornblunth A. Rubin DT, et al. Rev Gastroenterol Disord. 2005;5 Suppl 3:S10-5. Rev Gastroenterol Disord. 2005. PMID: 17713454 Review.

3

Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.

Cohen RD, Lewis JR, Turner H, Harrell LE, Hanauer SB, Rubin DT. Cohen RD, et al. Among authors: rubin dt. Inflamm Bowel Dis. 2012 Jan;18(1):10-6. doi: 10.1002/ibd.21707. Epub 2011 Mar 31. Inflamm Bowel Dis. 2012. PMID: 21456032 Clinical Trial.

4

Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data.

Rubin DT, Uluscu O, Sederman R. Rubin DT, et al. Inflamm Bowel Dis. 2012 Dec;18(12):2225-31. doi: 10.1002/ibd.22925. Epub 2012 Feb 22. Inflamm Bowel Dis. 2012. PMID: 22359399

5

Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center.

Sakuraba A, Keyashian K, Correia C, Melek J, Cohen RD, Hanauer SB, Rubin DT. Sakuraba A, et al. Among authors: rubin dt. Inflamm Bowel Dis. 2013 Mar;19(3):621-6. doi: 10.1097/MIB.0b013e31827eea78. Inflamm Bowel Dis. 2013. PMID: 23429449 Free PMC article.

6

Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease.

Sakuraba A, Annunziata ML, Cohen RD, Hanauer SB, Rubin DT. Sakuraba A, et al. Among authors: rubin dt. Inflamm Bowel Dis. 2013 Nov;19(12):2577-83. doi: 10.1097/MIB.0b013e3182a8df32. Inflamm Bowel Dis. 2013. PMID: 24132161

7

The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease.

Chapman CG, Rubin DT. Chapman CG, et al. Among authors: rubin dt. Gastrointest Endosc Clin N Am. 2014 Jul;24(3):353-65. doi: 10.1016/j.giec.2014.03.008. Epub 2014 May 6. Gastrointest Endosc Clin N Am. 2014. PMID: 24975527 Free PMC article. Review.

8

Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease.

Stein AC, Rubin DT, Hanauer SB, Cohen RD. Stein AC, et al. Among authors: rubin dt. Inflamm Bowel Dis. 2014 Oct;20(10):1722-8. doi: 10.1097/MIB.0000000000000146. Inflamm Bowel Dis. 2014. PMID: 25171509

9

Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis.

Colman RJ, Rubin DT. Colman RJ, et al. Among authors: rubin dt. J Crohns Colitis. 2014 Dec;8(12):1569-81. doi: 10.1016/j.crohns.2014.08.006. Epub 2014 Sep 13. J Crohns Colitis. 2014. PMID: 25223604 Free PMC article. Review.

10

Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.

Colman RJ, Rubin DT. Colman RJ, et al. Among authors: rubin dt. J Crohns Colitis. 2015 Apr;9(4):312-7. doi: 10.1093/ecco-jcc/jjv027. Epub 2015 Jan 23. J Crohns Colitis. 2015. PMID: 25616487 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

507 results

Search Page

Filters